Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led group
Canadian medical device company Angiotech Pharmaceuticals Inc has agreed to be bought by a consortium led by U.S. healthcare investment firm Vivo Capital and China's ZQ Capital. The latter are joined by GSO Capital Partners, China Orient Asset Management (International) Holding and Fung Shing Investments. Terms were not released for the deal, which is expected to close in the first quarter of 2016. Vancouver-based Angiotech develops and makes branded, private label, and original equipment manufacturer (OEM) surgical instruments. Its existing investors include Blue Mountain Capital, Courage Capital Management and Cetus Capital.
19 December 2016•5 mins read
